References
- Cambau E, Sougakoff W, Besson M, Truffot-Pernot C, Grosset J, Jarlier V. Selection of a gyrA mutant of Mycobacterium tuberculosis resistant to fluoroquinꠀ olones during treatment with ofloxacin. J Infect Dis 1994;170:479-83
- Grosset JH. Treatment of tubeculosis in HIV infection. Tuberc Lung Dis 1992;73:378-83 https://doi.org/10.1016/0962-8479(92)90044-K
- Tsukamura M, Nakamura E, Yoshii S, Amano H. Therapeutic effect of a new antibacterial substance ofloxacin (DL8280) on pulmonary tuberculosis. Am Rev Respir Dis 1985;131:352-6
- Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN, et al. American Thoracis Society/Centers for Disease Control and Prevention/ Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003;167: 603-62 https://doi.org/10.1164/rccm.167.4.603
- Crofton J, Chaulet P, Maher D, Grosset J, Harris W, Horne N, Iseman M, Watt B. Guidelines for the management of drug-resistant tuberculosis. Geneva: World Health Organization; 1997
- Casal M, Ruiz P, Herreras A. Study of the in vitro susceptibility of M. tuberculosis to ofloxacin in Spain. Int J Tuberc Lung Dis 2000;4:588-91
- Hoffner SF, Gezelius I, Olsson-Liljequist B. In vitro activity of fluorinated quinolones and macrolides against drug-resistant Mycobacterium tuberculosis. J Antimicrob Chemother 1997;40:885-8 https://doi.org/10.1093/jac/40.6.885
- Yu MC, Suo J, Lin TP, Luh KT. In vitro activity of ofloxacin against Mycobacterium tuberculosis. J Formos Med Assoc 1997;96:13-6
- Takiff H, Salazar L, Guerrero C, Philipp W, Huang WM, Kreiswirth B, et al. Cloning and nucleotide seꠀ quence of the Mycobacterium tuberculosis gyrA and gyrB genes, and characterization of quinolone resistance mutations. Antimicrob Agents Chemother 1994; 38:773-80
- Kim SJ, Bai GH, Hong YP. Drug resistant tuberꠀ culosis in Korea, 1994. Int J Tuberc Lung Dis 1997;1: 302-8
- Sullivan EA, Kreiswirth BN, Palumbo L, Kapur V, Musser JM, Ebrahimzadeh A, et al. Emergence of fluoroquinolone-resistant tuberculosis in New York City. Lancet 1995;345:1148-50 https://doi.org/10.1016/S0140-6736(95)90980-X
- Dong Y, Xu C, Zhao X, Domagala J, Drlica K. Fluoꠀ roquinolne action against mycobacteria: effects of C-8 substituents on growth, survival, and resistance. Antimicrob Agents Chemother 1998;42:2978-84
- Xu C, Kreiswirth BN, Sreevatsan S, Musser JM, Drlica K. Fluoroquinolone resistance associated with specific gyrase mutations in clinical isolates of multidrug resistant Mycobacterium tuberculosis. J Infect Dis 1996; 174:1127-30
- Dong Y, Zhao X, Kreiswirth BN, Drlica K. Mutant prevention concentration as a measure of antibiotic potency: studies with clinical isolates of Mycobacterium tuberculosis. Antimcirob Agents Chemother 2000; 44:2581-4 https://doi.org/10.1128/AAC.44.9.2581-2584.2000
- Zhao BY, Pine R, Domagala J, Drlica K. Fluoroquiꠀ nolone action against clinical isolates of Mycobacterꠀ ium tuberculosis: effects of a C8-methoxyl group on survival in liquid media and in human macrophages. Antimicrob Agents Chemother 1999;43:661-6
- Drlica K, Zhao X. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol Mol Biol Rev 1997;61: 377-92
- Hiasa H, Yousef DO, Marians KJ. DNA strand cleavage is required for replication fork arrest by a frozen topoisomerase-quinolone DNA ternary complex. J Biol Chem 1996;271:26424-9 https://doi.org/10.1074/jbc.271.42.26424
- Manes SH, Pruss GJ, Drlica K. Inhibition of RNA synthesis by oxolinic acid is unrelated to average DNA supercoiling. J Bacteriol 1983;155:420-3
- Cheng AF, Yew WW, Chan EW, Chin ML, Hui MM, Chan RC. Multiplex PCR amplimer conformation analysis for rapid detection of gyrA mutations in fluoroquinolone-resistant Mycobacterium tuberculosis clinical isolates. Antimicrob Agents Chemother 2004;48: 596-601 https://doi.org/10.1128/AAC.48.2.596-601.2004
- Perlman DC, el Sadr WM, Heifets LB, Nelson ET, Matts JP, Chirgwin K, et al. Susceptibility to levofloxacin of Mycobacterium tuberculosis isolates from patients with HIV-related tuberculosis and characterization of a strain with levofloxacin monoresistacne. AIDS 1997;11:1473-8
- Kim BJ, Kang YS, Park SK. Activity of moxifloxacin against ofloxacin-resistant Mycobacterium tuberculosis: a study of cross-resistance between ofloxacin and moxifloxacin. Tuberc Respir Dis 2004;57:405-10
- Ji B, Lounis N, Maslo C, Truffot-Pernot C, Bonnafous P, Grosset J. In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis. Antimicrob Agents Chemother 1998;42: 2066-9
- Alvirez-Freites E, Carter J, Cynamon MH. In vitro and in vivo activities of gatifloxacin against Mycobacterium tuberculosis. Antimicrob Agents Chemother 2002;46:1022-5 https://doi.org/10.1128/AAC.46.4.1022-1025.2002
- Ji B, Lounis N, Truffot-Pernoc C, Grosset J. In vitro and in vivo activities of levofloxacin against Mycobacterium tuberculosis. Antimicrob Agents Chemother 1995;39:1341-4
- Canetti G, Fox W, Khomenko A, Mahler H, Menon N, Mitchison DA, et al. Advances in techniques of testing mycobacterial drug sensitivity and the use of sensitivity tests in tuberculosis control programmes. Bull Worl Health Organ 1969;41:21-43